Edwards Lifesciences Beats Q2 Earnings On Demand Recovery, Boosts FY2021 Guidance; Analysts Raise Price Target
July 30, 2021 at 11:33 AM EDT
Edwards Lifesciences a cardio device company, reported Q2 earnings of $489.5 million, or $0.64, ahead of the consensus of $0.55.